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Psoriasis is an inflammatory skin disorder with aberrant regulation of keratinocytes and immunocytes. Although it
is well known that uncontrolled keratinocyte proliferation is largely driven by proinflammatory cytokines from
the immunocytes, the functional role of keratinocytes in the regulation of immunocytes is poorly understood.
Recently, we found that tripartite motif-containing protein 32 (Trim32), an E3-ubiquitin ligase, is elevated in the
epidermal lesions of human psoriasis. We previously showed that Trim32 binds to the protein inhibitor of
activated STAT-Y (Piasy) and mediates its degradation through ubiquitination. Interestingly, the Piasy gene is
localized in the PSORS6 susceptibility locus on chromosome 19p13, and Piasy negatively regulates the activities
of several transcription factors, including NF-kB, STAT, and SMADs, that are implicated in the pathogenesis of
psoriasis. In this study, we show that Trim32 activates, and Piasy inhibits, keratinocyte production of CC
chemokine ligand 20 (CCL20), a psoriatic chemokine essential for recruitment of DCs and T helper (Th)17 cells
to the skin. Further, Trim32/Piasy regulation of CCL20 is mediated through Piasy interaction with the RelA/p65
subunit of NF-kB. As CCL20 is activated by Th17 cytokines, the upregulation of CCL20 production by Trim32
provides a positive feedback loop of CCL20 and Th17 activation in the self-perpetuating cycle of psoriasis.
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INTRODUCTION
CC chemokine ligand 20 (CCL20) is an inflammatory chemo-
kine responsible for recruitment of leukocytes to sites of
injury and inflammation. It is mainly expressed in surface
epithelial cells such as keratinocytes (Homey et al., 2000),
bronchial epithelial (Reibman et al., 2003), and intestinal
epithelial cells (Fujiie et al., 2001). CCL20 expression from
keratinocytes is induced by proinflammatory cytokines such
as tumor necrosis factor (TNFa), IL-1, and IL-17 (Homey
et al., 2000; Nograles et al., 2008; Harper et al., 2009). In
contrast to the promiscuous nature of many other chemokines
and their receptors, CC chemokine receptor6 (CCR6) is
the only known receptor for CCL20. CCR6 is expressed
in a variety of immunocytes, including neutrophils, memory
B-cells, Treg, immature dendritic cells (DCs), and T helper
(Th)17 cells. CCL20/CCR6 play important roles in the
chemostasis of immunocytes, particularly for those in the
Th17 pathway. CCR6 is induced by the nuclear receptor
RORgammat (Manel et al., 2008), and found in virtually
all Th17 cells (Singh et al., 2008). Moreover, CCR6 is
essential for the pathogenesis of encephalomyelitis and
psoriasis in animal models (Hedrick et al., 2009; Reboldi
et al., 2009).
Th17 activation is a defense mechanism against extra-
cellular infection in tissues (Ghilardi and Ouyang, 2007). The
receptors for Th17 cytokines are expressed in a variety of
epithelial cells, including keratinocytes. Th17 cytokines
contribute to tissue immunity through (1) production of
antimicrobial peptides, (2) recruitment of immunocytes
through induction of chemokines such as CCL20, and (3)
tissue repair by enhancing epithelial proliferation (Zheng
et al., 2007). The Th17-signaling pathway is tightly controlled
to ensure tissue homeostasis, and is terminated after infection
is ablated and tissue repair is complete. However, Th17
signaling is persistently activated in psoriasis (Blauvelt, 2008).
Recruitment of Th17 cells by CCL20 and induction of CCL20
from keratinocytes by Th17 cytokines in psoriasis highlights
the critical role of CCL20 in Th17 activation and psoriasis
pathogenesis. Yet, regulation of CCL20 induction in
keratinocytes is largely unknown.
Tripartite motif-containing protein 32 (Trim32) is a scaffold
protein with E3-ubiquitin ligase activity (Ozato et al., 2008).
We found that Trim32 contributes to survival of keratinocytes
under conditions that induce terminal differentiation and
apoptosis (Horn et al., 2004). Furthermore, we identified
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protein inhibitor of activated STAT-Y (Piasy) as a Trim32
physiological substrate (Albor et al., 2006), where Trim32
mediates Piasy ubiquitylation and degradation in keratinocytes.
Piasy is a transcriptional repressor for a number of transcription
factors with roles in inflammation and keratinocyte prolifera-
tion, such as STATs, SMADs, and NF-kB (Shuai and Liu, 2005).
The PIASY gene is localized in a psoriasis-susceptibility locus
(PSORS6) on chromosome 19p13 (Lee et al., 2000); however,
the genetic alterations responsible for the pathogenesis of
psoriasis in this locus remain to be identified. The fact that Piasy
regulates a number of factors whose activation is associated
with psoriasis-like phenotypes in mouse models, including
constitutive NF-kB activation by IkBa deletion (Klement et al.,
1996), epidermal overexpression of STAT3 (Sano et al., 2005),
and transforming growth factor-b, which activates Smads
(Li et al., 2004), highlights a central role for Trim32 and Piasy
in psoriasis pathogenesis.
In this study, we found that Trim32 is elevated in psoriatic
epidermis. Furthermore, we identified CCL20 as a downstream
target of Trim32. Trim32 activates, and Piasy inhibits,
keratinocyte production of CCL20 in mouse and in human
keratinocytes. Further molecular dissection of this pathway
revealed Trim32/Piasy regulation of CCL20 through NF-kB,
mediated by Piasy interaction with the RelA/p65 subunit of
NF-kB. As CCL20 is activated by Th17 cytokines, the upregu-
lation of CCL20 production by Trim32 provides a novel
positive feedback loop and direct keratinocyte role of CCL20
and Th17 activation in the self-perpetuating cycle of psoriasis.
RESULTS
Trim32 is upregulated in psoriatic epidermis
Trim32 is an E3-ubiquitin ligase that inhibits apoptosis in
normal keratinocytes in response to UV light and TNFa (Horn
et al., 2004). On the basis of reports of resistance to apoptosis
as one of the common features of psoriatic keratinocytes
(Wrone-Smith et al., 1997), we tested Trim32 expression in
lesional specimens from human psoriasis patients, as
compared with that in uninvolved control epidermis (Figure 1a).
We found Trim32 overexpression in 20 out of 33 psoriasis
specimens by immunohistochemical staining, with elevated
Trim32 in the basal and spinous epidermal cell layers.
Indirect immunofluorescence analysis revealed that Trim32
expression is predominantly cytoplasmic in the psoriatic
keratinocytes (Figure 1b), as expected on the basis of previous
studies (Reymond et al., 2001; Albor et al., 2006).
Regulation of psoriatic chemokine CCL20 by Trim32/Piasy
To explore how Trim32 might potentially contribute to the
pathogenesis of psoriasis, we analyzed the expression of a
panel of psoriatic cytokines and chemokines in keratinocytes
infected with Trim32 or Piasy adenoviruses. We found that
CCL20 expression was significantly increased in keratino-
cytes with Trim32 adenovirus and decreased in keratinocytes
with Piasy adenovirus, as compared with those infected with
GFP adenovirus (Figure 2a). In addition, CCL20 expression is
reduced in primary keratinocytes isolated from Trim32-null
mice as compared with those from their wild-type littermates
(Figure 2b).
Trim32 correlates with CCL20 expression in psoriasis
CCL20 is a psoriatic chemokine overexpressed in psoriatic
epidermis (Homey et al., 2000). To test whether Trim32
expression correlated with CCL20 expression, we performed
immunostaining of tissue sections for each of these antigens
in human psoriatic skin specimens versus uninvolved skin
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Figure 1. Elevated Trim32 expression in human psoriasis. (a) Immuno-
histochemical analysis of Trim32 expression in psoriasis specimens. Trim32
was visualized in paraffin sections using 0.2mgml1 chicken anti-Trim32
antibody and stained by the ABC technique. Trim32 level was elevated
in the epidermis of psoriatic lesions relative to that in uninvolved skin
(200 magnification). (b) Indirect immunofluorescence analysis of
Trim32 expression in psoriasis specimens. Trim32 was visualized with
chicken anti-Trim32 antibody followed by Texas red secondary antibody
(600 magnification). The nucleus was stained with Hoechst 33342. The
micrographs are representative of 20 Trim32-positive specimens out of 33
psoriatic skin specimens. Bar¼ 50 mm.
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Figure 2. Regulation of CCL20 expression in keratinocytes by Trim32 and
Piasy. (a) CCL20 mRNA expression in the mouse keratinocyte line 291
infected with adenovirus expressing GFP, Trim32, or Piasy. (b) Analysis of
CCL20 mRNA in primary mouse keratinocytes isolated from Trim32-null mice
(Trim32/) and wild-type littermates (Wt). CCL20 mRNA was normalized
to GAPDH. The data are representative of three independent experiments
for Figure 1a and two independent experiments for Figure 1b (**Po 0.01;
***Po 0.001).
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controls (Figure 3). CCL20 was not detectable in uninvolved
skin. However, CCL20 was detected along with Trim32
overexpression in a majority of psoriatic skin specimens.
CCL20 was detected in 23 out of 33 psoriasis specimens
obtained from 33 different patients, correlating with Trim32
positivity in 19 cases. Lack of Trim32 correlated with lack of
CCL20 expression in nine additional cases. Thus CCL20
expression in psoriatic lesions correlated with Trim32 status
in 87% of the psoriatic specimens (Figure 3).
Trim32 sensitizes keratinocytes to TNFa- and IL-17A-induced
CCL20 expression
To define the role of CCL20 in T-cell response, we evaluated
CCL20 expression in keratinocytes treated with Th1 (IFN-g,
IL-2, IL-12), Th2 (IL-4, IL-13), and Th17 (IL-17A, TNFa)
cytokines. TNFa and IL-17A showed potent effects on CCL20
expression in keratinocytes (Figure 4a), while neither Th1 nor
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Figure 3. Trim32 and CCL20 expression in human psoriasis. Paraffin-
embedded psoriatic lesional tissues from 33 patients were sectioned serially
and stained with chicken anti-Trim32 antibody and goat anti-CCL20 antibody
(100 magnification). The results are summarized in the table. Correlation of
Trim32 overexpression with CCL20 expression was statistically significant
(*two-tailed Fisher’s exact test, P-value¼ 0.00015). Bar¼ 50mm.
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Figure 4. Regulation of Th17 induced CCL20 by Trim32 and Piasy.
(a) CCL20 mRNA was measured by quantitative real-time PCR in mouse 291
keratinocytes treated with the indicated cytokines and LPS. (b) CCL20 mRNA
was measured by quantitative real-time PCR in mouse 291 keratinocytes
infected overnight with adenovirus expressing GFP, Trim32, or Piasy, then
treated with indicated cytokines for 4 hours. CCL20 mRNA was normalized
to GAPDH. (c) CCL20 protein was measured by ELISA in mouse 291
keratinocytes infected overnight with adenovirus expressing GFP, Trim32,
or Piasy, then treated with indicated cytokines for 6 hours. (d) The human
keratinocyte line HEKnV was infected with adenovirus expressing GFP,
Trim32, or Piasy, and then treated with the indicated cytokines for 6 hours.
CCL20 protein was measured from the culture supernatant by ELISA.
Data are representative of three independent experiments. Statistical analysis
was conducted by one-way analysis of variance followed by Bonferroni
post-test (**Po 0.01; ***Po 0.001).
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Th2 cytokines showed any significant effect on CCL20
expression. As activated Th17 cells produce both IL-17A
and TNFa, we evaluated their combined effects on CCL20
induction. Although TNFa is also produced from other Th
cells, the enhanced induction of CCL20 by the combined
treatment of IL-17A and TNFa is consistent with CCL20 as a
Th17 chemokine regulated by Th17 cytokines.
To test whether Trim32/Piasy regulates the expression of
CCL20 in response to TNFa and IL-17A, we measured CCL20
expression in keratinocytes infected with Trim32- or Piasy-
expressing adenoviruses, followed by treatment with TNFa or
IL-17A. Trim32 significantly increased, whereas Piasy
repressed, TNFa and IL-17A induction of CCL20 expression
(Figure 4b). These effects of Trim32 and Piasy on the
induction of CCL20 by TNFa or IL-17A were confirmed by
ELISA analysis of CCL20 protein expression in both mouse
(Figure 4c) and human (Figure 4d) keratinocytes. Trim32
showed enhanced induction of CCL20 by TNFa or IL-17A,
but not by IL-17F, IL-13, or IFN-g. The cooperation of Trim32
expression with TNFa or IL-17 signaling to induce CCL20
expression in keratinocytes suggests that Trim32 is a positive
regulator that targets the rate-limiting steps in the TNFa- and
IL-17-signaling pathways.
CCL20 regulation by Piasy is mediated through the p65/RelA
subunit of NF-jB
The regulation of TNFa and IL-17 induced CCL20 by Trim32/
Piasy suggests Trim32/Piasy acts at a common pathway
between TNFa and IL-17. In fact, NF-kB is a common
downstream effector of TNFa, IL-17, IL-1, and lipopolysac-
charide (LPS). As our previous results showed that NF-kB is
regulated by Trim32/Piasy (Albor et al., 2006), we evaluated
the effect of Trim32 and Piasy on NF-kB dependent CCL20
expression. We found that CCL20 is induced upon transfec-
tion of a constitutively active p65/RelA subunit of NF-kB
(Figure 5a), but that p65-mediated CCL20 expression was
only marginally increased by co-transfection of Trim32. This
suggests that p65 acts downstream of Trim32, and therefore
bypasses the regulation of CCL20 expression by Trim32. Note
that the overall induction of CCL20 by Trim32 plasmid
transfection (9.6-fold) was less than CCL20 induction by
Trim32 adenovirus (20-fold in Figure 4), consistent with
plasmid transfection being less efficient than adenoviral
infection. p65-dependent CCL20 expression was significantly
repressed by co-transfection of Piasy, suggesting that p65 is a
target of Piasy. This is supported by Piasy’s association with
p65, as detected by co-immunoprecipitation of endogenous
p65 with Flag-tagged Piasy in 291 keratinocytes (Figure 5b),
suggesting that CCL20 regulation by Trim32/Piasy is
mediated through NF-kB.
DISCUSSION
Psoriasis is a chronic inflammatory skin disorder character-
ized by epidermal hyperproliferation and immunocyte
infiltration (Lowes et al., 2007; Nickoloff et al., 2007).
T-cell-derived cytokines have been viewed prevalently as the
driving force for aberrant keratinocyte proliferation and
differentiation, whereas keratinocytes are generally viewed as
the downstream effectors of T-cell activation. Yet, unlike many
other autoimmune diseases such as systemic lupus erythema-
tosus and pemphigus vulgaris, psoriasis is triggered and
exacerbated by external insults such as microbial infections
and physical injury (Koebner phenomenon), suggesting that
defects in the immune system alone are not sufficient for
psoriasis pathogenesis. The perturbation of keratinocyte
response to external insults may contribute to the pathogenesis
of psoriasis through chemokine production to recruit immu-
nocytes. CCL20 is a chemokine abundant in psoriatic plaques
(Homey et al., 2000; Kryczek et al., 2008; Harper et al., 2009),
and is induced by proinflammatory cytokines. In addition,
CCL20 can be induced by physical stimuli, such as tape
stripping of skin (Schmuth et al., 2002) and dynamic
compression of chondrocytes (Haudenschild et al., 2008).
Induction of CCL20 can also be achieved through infections by
bacteria such as Staphylococcus aureus (Fahy et al., 2004) and
Streptococcus mutans (Takahashi et al., 2008), with different
toll-like receptors in keratinocytes specific to different types of
microbes. As keratinocytes constitute the first line of defense to
protect the body from external insults, CCL20 production from
keratinocytes could be an initial trigger for Th17 activation,
and aberrant CCL20 induction in keratinocytes may contribute
to the pathogenesis of psoriasis.
In this study, we showed upregulation of Trim32, an E3-
ubiquitin ligase, in psoriatic epidermis and identified Trim32
and its substrate Piasy as regulators of CCL20. Trim32
increases CCL20 induction by TNFa and IL-17 in keratino-
cytes. Systematic analysis of CCL20 induction in response to
cytokines revealed that CCL20 is induced by Th17 but not
Th1 or Th2 cytokines. This indicates that CCL20 is a
chemokine specific to Th17 activation. These results are
consistent with the results of Harper et al. (2009) demonstrat-
ing that CCL20 is induced by TNFa and IL-17A. In
conjunction with CCL20 induction by Th17 cytokines, the
involvement of CCL20 in Th17 activation is also supported by
(1) CCL20 recruitment of CCR6-positive CD11cþ DCs that
produce IL-23 for Th17-cell activation (Lee et al., 2004); (2)
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Figure 5. Piasy regulates CCL20 through p65/RelA subunit of NF-jB.
(a) CCL20 mRNA was measured in 291 keratinocytes transfected with plasmids
expressing GFP, p65, Trim32þ p65, or Piasyþp65. Data are representative of
two independent experiments. Statistical analysis of Trim32 and Piasy effect
was conducted relative to p65 alone control (*Po0.05). (b) Piasy interacts
with endogenous p65 in keratinocytes. Flag-tagged Piasy and Flag-tagged Erk
(negative control) were transfected into 291 keratinocytes. Bound p65 was
immunoprecipitated with an anti-Flag antibody and visualized by
immunoblotting with an anti-p65 antibody.
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high CCR6 expression in virtually all Th17 cells but not in
Th1 and Th2 cells (Singh et al., 2008; Yamazaki et al., 2008);
and (3) CCL20 overexpression in psoriatic epidermis (Homey
et al., 2000). Therefore, CCL20 expression in keratinocytes
could be a key component in maintaining the self-perpetuat-
ing cycle of Th17 activation in psoriasis.
As a tissue immune defensive mechanism, the Th17-
signaling pathway is activated upon exposure to pathogens or
tissue injury, and is tightly controlled to ensure tissue
homeostasis (Ghilardi and Ouyang, 2007). Th17 signaling is
terminated after infection is ablated and tissue repair is
complete. The persistent Th17 activation in psoriasis suggests
that defects exist in Th17 signal regulation in psoriasis.
Persistent Th17 activation in psoriatic skin is characterized by
(1) infiltration of IL-23-producing DCs and Th17 cells, and (2)
epidermal overexpression of Th17 chemokines. As recruit-
ment of Th17 cells and IL-23-producing DCs is an essential
step for Th17 activation, uncontrolled CCL20 production by
keratinocytes could be central to persistent Th17 activation in
psoriasis. In this study, we have demonstrated that CCL20
induction by TNFa and IL-17A is enhanced by Trim32 and
attenuated by Piasy (Figure 4). Thus, Trim32 overexpression
in human psoriatic lesions observed in this study provides a
plausible mechanism for how keratinocytes in epidermis
could contribute to excessive CCL20 production in psoriasis.
As Piasy is a substrate of Trim32, Piasy alterations could be
primary causes of aberrant CCL20 induction in psoriasis cases
without elevated Trim32. In this regard it will be interesting to
determine whether the PIASY gene is functionally involved in
the psoriasis susceptibility associated with the PSORS6 locus
on chromosome 19p13 (Lee et al., 2000). As Piasy is also a
negative regulator for NF-kB, Smad, and Stat transcription
factors that have been implicated in the development of
psoriasis-like phenotypes in animal models, taking advantage
of animal models and genetic approaches will help to further
define the role of the Trim32/Piasy axis in Th17 activation
and psoriasis pathogenesis.
So far, the mechanism of CCL20 regulation by the Trim32/
Piasy axis is largely unknown. The magnitude of CCL20
induction enhanced by Trim32 suggests that Trim32 acts at
the rate-limiting step in CCL20 regulation. As NF-kB is the
common downstream effector of TNFa, IL-1, IL-17, and LPS,
we focused our study on the NF-kB pathway. Although
CCL20 induction by TNFa and IL-17 was significantly
sensitized by Trim32 (Figure 4), CCL20 induction by the
p65/RelA subunit of NF-kB was only marginally enhanced by
Trim32 (Figure 5a). Bypassing the action of Trim32 by the
constitutively active p65/RelA suggests that p65/RelA is the
downstream effector of Trim32. Our evidence that p65/RelA
is a Piasy-interacting protein, and that p65/RelA-mediated
CCL20 induction was repressed by Piasy (Figure 5a), suggests
that p65/RelA is a target regulated by the Trim32/Piasy axis in
CCL20 expression.
Taken together, our results show that Trim32 and Piasy
can regulate CCL20 in mouse and human keratinocytes; that
Trim32 and CCL20 expression positively correlate in psoriasis
lesional samples; and that Trim32 antigen activity is elevated
in psoriatic epidermis. These results provide evidence for a
novel pathway by which CCL20 is regulated in keratinocytes,
and by which keratinocytes may contribute to Th17’s role in
psoriasis. Further study to define the mechanism of CCL20
regulation by the Trim32/Piasy axis in keratinocytes will be
essential to develop novel therapeutic approaches that target
these E3 ligases to disrupt the self-perpetuating cycle of Th17
activation in psoriasis.
MATERIALS AND METHODS
Keratinocyte cell cultures
The primary mouse keratinocyte cell strain 291 was derived from
neonatal mouse skin and displays normal regulation of proliferation
and differentiation by extracellular Ca2þ characteristic of primary
epidermal cultures (Kulesz-Martin et al., 1985). Primary mouse
keratinocytes were isolated from neonatal Trim32-knockout mice
epidermis and their wild-type littermates. These cells were main-
tained in low-calcium Eagle’s medium (LCEM, final concentration
of 0.03–0.05mM Ca2þ ) as described by Kulesz-Martin et al. (1988)
and Dlugosz et al. (1995). The human keratinocyte HEKnV was
cultured in EpiLife keratinocyte medium supplemented with a semi-
defined human keratinocyte growth supplement (Cascade Biologics,
Portland, OR) as described by Iordanov et al. (2002).
Adenoviral production and infection
The recombinant Trim32 and Piasy adenoviruses were generated as
described using Adeno-X (Clontech, Mountain View, CA) (Liu et al.,
2004). The recombinant Trim32 adenovirus was characterized using an
anti-Trim32 antibody to detect Trim32 expression in 291 keratinocytes
infected with the virus. The viral particles were titered by immunostain-
ing of Trim32 in 291 keratinocytes infected with limiting dilutions of
virus. The minimum number of viral particles required for 100%
infection of 291 keratinocytes was calibrated for experiments.
Cytokine treatment
Once the keratinocyte culture reached 100% confluence, the
medium was replaced with LCEM without the fibroblast-conditioned
media. The mouse and human keratinocyte cultures were treated
with species-specific cytokines, TNFa (20 ngml1), 1mgml1 LPS
(Sigma, St Louis, MO), IFNg (20 ngml1), IL-2 (20 ngml1), IL-4
(50 ngml1), IL-13 (50 ngml1), IL-17A (100 ngml1), IL-17F
(100 ngml1), or IL-22 (100 ngml1; purchased from Peprotech,
Rocky Hill, NJ).
Quantitative real-time PCR for CCL20
Triplicate qPCR reactions (15ml) for each sample and primer set were
performed using a 384-well plate (Applied Biosystems, Foster City, CA),
using the Ccl20-gene-specific primers (6mM each, validated for linearity
and target specificity) Fwd, TGCTCTTCCTTGCTTTGGCATGGGTA and
Rev, TCTGTGCAGTGATGTGCAGGTGAAGC, in the presence of UDP-
N-glycosylase (Invitrogen, Carlsbad, CA) and SYBR-Green-I dye (Applied
Biosystems). Gene expression data were collected using a 7900HT
thermocycler and SYBR-Green-I fluorescence was analyzed by the DDCt
method (Applied Biosystems). The relative Ccl20mRNA was normalized
with GAPDH.
Keratinocyte transfection and immunoprecipitation
291 keratinocytes were transfected with a Flag-tagged Piasy vector
(Albor et al., 2006) using the Mirus transfection reagent (Mirus Bio
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LLC, Madison, WI) when the culture reached 70% confluence. The
cell lysates were collected in RIPA buffer (150mM NaCl, 1% NP-40,
0.5% deoxycholate, 0.1% SDS, 10mM EDTA, 50mM Tris–HCl, pH
8.0) and subjected to immunoprecipitation with agarose beads
conjugated to anti-Flag antibody, clone M2 (Sigma). The bound
proteins were eluted for immunoblotting with anti-p65/RelA anti-
body, clone C20 (Santa Cruz Biotechnology, Santa Cruz, CA).
Indirect immunofluorescence and immunohistochemistry
Archival human psoriasis lesional skin specimens biopsied and
diagnosed in the OHSU Department of Dermatology were accessed
with approved OHSU IRB protocol. Uninvolved human skin controls
were obtained from non-psoriasis donors undergoing surgery at the
Department of Dermatology or Otolaryngology. Non-specific bind-
ing of antibody was blocked with PAB (PBS, 0.1% sodium azide,
0.5% BSA) containing 10% normal goat serum for CCL20 or 10%
blokhen (AVES Lab, Portland, OR) for Trim32. The sections were
then incubated with an affinity-purified chicken anti-Trim32 anti-
body generated in our laboratory (Albor et al., 2006) or with a goat
anti-CCL20 antibody, clone AF360 (R&D Systems, Minneapolis,
MN) overnight at 4 1C. The specificity of the chicken anti-Trim32
antibody was verified by immunoblotting and immunostaining as
described by Albor et al. (2006) and detailed in Supplementary
Figure S1. The staining signal was visualized by the ABC approach
(Vector Laboratories, Burlingame, CA) and counterstaining was
performed with hematoxylin. Immunofluorescence staining of
Trim32 was performed with the Texas red secondary antibody. The
nucleus was stained with 1 mgml1 Hoechst 33342.
Statistics
The data were expressed as mean±SD. The statistical significance of
CCL20 regulation by Trim32 and Piasy was determined by two-tailed
Student’s t test (Figures 2 and 5) and one-way analysis of variance
followed by Bonferroni post-test (Figure 4). Statistical significance of
correlated expression of Trim32 and CCL20 (Figure 3) was
determined by two-tailed Fisher’s exact test.
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